Emyria (ASX:EMD) to offer digital health monitoring services in WA

Summary

  • ASX-listed drug development company Emyria has obtained a grant to advanced digital and mental health monitoring.
  • The grant aims to assess advanced digital health monitoring utility in vulnerable populations.
  • Openly, the remote monitoring service, will also provide support and monitor patients during the Company’s forthcoming clinical trials.

ASX-listed data-backed, drug development player Emyria Limited (ASX:EMD) announced that Openly will play a central role in a recently awarded grant from Future Health Research and Innovation Fund of Western Australia. Openly is Emyria’s advanced remote monitoring digital health service.

Following the update, EMD shares moved up and were trading 7.142% higher at A$0.150 (at AEDT 12:24 PM).

Emyria to provide advanced digital and mental health monitoring

Emyria updated the market that as part of the grant, its remote monitoring service, Openly will offer monitoring services for advanced digital and mental health.

The successful grant is titled: “An advanced digital monitoring and engagement platform for at-risk and confirmed COVID-19 individuals”. It aims to evaluate the efficiency of advanced digital health monitoring in vulnerable patients.

   Source: © Aiconimage | Megapixl.com

With this grant, Emyria will focus on improving the engagement amongst aged and ethnic populations. It will also focus on improving mental health evaluation as well as monitoring for under remote care.

  • In this grant, Emyria will take the lead.
  • The Company will take the lead of multidisciplinary collaboration, including key health services and universities of Western Australia.
  • The grant will also extend partnership of Emyria with Mt Sinai, New York.
  • Emyria also disclosed that Openly would also support and monitor patients during the Company’s upcoming clinical trials.

These pivotal studies will provide support in the registration of EMD-003, Emyria’s leading drug candidate. The studies focus on unmet medical needs in psychological distress as well as the symptoms of stress, anxiety, and depression.

Openly in a nutshell

Openly supports digital health and wellness screening using smart mobile devices and backed by Emyria’s clinical team.

Initially, Openly was developed for assisting contactless remote COVID-19 screening management.

On 15 September 2020, Openly was registered as a Class 1 medical device in the Therapeutic Goods Administration (TGA).

  • Openly supports in the collection of real-world clinical information from individuals remotely such as heart rate and heart rate variability.
  • This information is presented to a clinical team who can act on that information.
  • When vital signs of physiological stress like heart rate variability alter from baseline, this can signal mental distress or early infection.

Emyria’s Managing Director, Dr Michael Winlo, said:

Dr Winlo also added the Company has been focusing on the development of digital health as well as remote monitoring technologies for enhancing the care of patients with unmet medical needs. Emyria focuses on catering complex patients and those having mental health indications.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK